Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ProMIS Neurosciences Inc
PMN
Healthcare
Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational...
discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PMN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(21)
•••
BottomBroker
X
View Profile
View Bullboard History
Comment by
BottomBroker
on Jan 09, 2025 10:46am
RE:RE:RE:RE:RE:ARIA-E
From another slide further down in the presentation... ProMIS platform enabled generation of PMN310 which does not bind plaque or monomers, only oligomers Attempts by others to selectively target
...more
(12)
•••
Speyeder999
X
View Profile
View Bullboard History
Comment by
Speyeder999
on Jan 09, 2025 7:42am
RE:RE:RE:RE:ARIA-E
On slide 14 of their most recent overview regarding Phase 1a, we find the mention No ARIA to be expected. So I'm confused. https://d1io3yog0oux5.cloudfront.net/_28c9a01cbe79b70ba7b8bd4e8fa5da15
...more
(106)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Jan 08, 2025 8:23pm
RE:RE:RE:RE:ARIA-E
WHY? G1945V
(93)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Jan 08, 2025 7:53pm
RE:RE:RE:ARIA-E
Testing for ARIA in healthy individuals would have been a big foolish mistake and waste of money.
(106)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Jan 08, 2025 9:43am
RE:RE:ARIA-E
If true, it would be a big mistake. ARIA is one of the biggest safety issues that PMN has been boasting about for years. G1945V
(12)
•••
Hafness
X
View Profile
View Bullboard History
Comment by
Hafness
on Jan 07, 2025 3:06pm
RE:What's the outlook ?
Pmn phase 1a safty data looks good. Phase 1b efficacy first readouts should come in around 6months. If they can show efficacy and no brain swelling. Possible buy out or partnership to finalize
...more
(12)
•••
Hafness
X
View Profile
View Bullboard History
Comment by
Hafness
on Jan 07, 2025 3:03pm
RE:ARIA-E
Gavin Malenfant responded and said Aria was not studied during first trail 1a
(12)
•••
Speyeder999
X
View Profile
View Bullboard History
Comment by
Speyeder999
on Jan 07, 2025 2:35pm
RE:Where’s retiredcop?
Yes, indeed. RC has been here for over 10 years and I miss the posts. I tell you who I really miss though is M101, you are sorely missed!
(4)
•••
jiggityjig456
X
View Profile
View Bullboard History
Post by
jiggityjig456
on Jan 07, 2025 1:47pm
Where’s retiredcop?
They used to be someone I trusted on this stock. Where did they go? Better yet, who were they? I often thought they might have been an insider.
(1)
•••
Thenorth1990
X
View Profile
View Bullboard History
Post by
Thenorth1990
on Jan 07, 2025 1:37pm
What's the outlook ?
as hoping if someone could summarize their expectations from this stock, I used to be heavy on this years ago. But when they didn't keep their promise with the covid testing stuff, I backed out
...more
(12)
•••
Hafness
X
View Profile
View Bullboard History
Comment by
Hafness
on Jan 06, 2025 11:31am
RE:RE:RE:RE:RE:RE:RE:ARIA-E
Nice. I will check it out
(93)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Jan 05, 2025 9:50pm
RE:RE:RE:RE:RE:RE:ARIA-E
Here it is: https://www.science.org/content/article/clinical-trial-participants-autopsy-brain-exam-stoke-alzheimers-drug-fears? Most straight-forward explanation of how current antibody treatments
...more
(93)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Jan 05, 2025 4:06pm
RE:RE:RE:RE:RE:ARIA-E
I think there was a publication in Science assessing the brain bleed effect of aducanumab or leqembi... something to do with plaques coating arteries in brain and plaque-targeting anti-bodies
...more
(106)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Jan 05, 2025 7:43am
RE:RE:RE:RE:ARIA-E
"aria-e would be a side effect in healthy subjects as well I would think." I don't see why not! I know from publications that before the trial begins, a baseline MRI scan is performed
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Alphamin Announces Record Fy2024 & Q4 2024 Tin Production Fy2025 Production Guidance Exploration Success
Have you held units of a TD mutual fund, other than through a discount broker? Learn more.
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*
Eminent's First Drill Hole Hits Significant Gold-Arsenic in Getchell Trend Analogue and Second Hole Drilling Commences
U.S. DOD Logistics Agency Highlights V.GPH Project to Develop Eco-Friendly Graphite-Based Fire-Fighting Material